BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
_256_384.jpg)
Visby Medical’s instrument-free PCR test to detect the SARS-CoV-2 virus can now be used to pool up to five patient samples using a single test
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
Subscribe To Our Newsletter & Stay Updated
